CA2710764A1 - Methodes ameliorant les performances et le tonus musculaires - Google Patents

Methodes ameliorant les performances et le tonus musculaires Download PDF

Info

Publication number
CA2710764A1
CA2710764A1 CA2710764A CA2710764A CA2710764A1 CA 2710764 A1 CA2710764 A1 CA 2710764A1 CA 2710764 A CA2710764 A CA 2710764A CA 2710764 A CA2710764 A CA 2710764A CA 2710764 A1 CA2710764 A1 CA 2710764A1
Authority
CA
Canada
Prior art keywords
subject
agonist
ampk
exercise
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2710764A
Other languages
English (en)
Inventor
Ronald M. Evans
Vihang A. Narkar
Reuben J. Shaw
Michael Downes
Ruth T. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/089124 external-priority patent/WO2008083330A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2710764A1 publication Critical patent/CA2710764A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2710764A 2007-12-28 2008-12-29 Methodes ameliorant les performances et le tonus musculaires Abandoned CA2710764A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2007/089124 WO2008083330A2 (fr) 2006-12-29 2007-12-28 Procédés permettant une amélioration des performances d'exercice
US11/966,851 2007-12-28
US11/966,851 US20080187928A1 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance
USPCT/US07/089124 2007-12-28
US8084108P 2008-07-15 2008-07-15
US61/080,841 2008-07-15
PCT/US2008/088466 WO2009086526A2 (fr) 2007-12-28 2008-12-29 Méthodes améliorant les performances et le tonus musculaires

Publications (1)

Publication Number Publication Date
CA2710764A1 true CA2710764A1 (fr) 2009-07-09

Family

ID=40825106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2710764A Abandoned CA2710764A1 (fr) 2007-12-28 2008-12-29 Methodes ameliorant les performances et le tonus musculaires

Country Status (5)

Country Link
EP (1) EP2234622A4 (fr)
JP (1) JP2011507970A (fr)
AU (1) AU2008345009A1 (fr)
CA (1) CA2710764A1 (fr)
WO (1) WO2009086526A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114396A4 (fr) 2006-12-29 2010-03-10 Salk Inst For Biological Studi Procédés permettant une amélioration des performances d'exercice
EP2409152A4 (fr) * 2009-03-20 2012-10-17 Salk Inst For Biological Studi Procédés pour moduler des rythmes circadiens
KR101698201B1 (ko) * 2010-05-20 2017-01-19 (주)뉴트리 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물을 포함하는 근육 증가 촉진, 항-피로 및 운동수행능력 향상용 조성물
RU2013114390A (ru) 2010-08-31 2014-10-10 СНУ Ар энд ДиБи ФАУНДЕЙШН Применение фетального репрограммирования посредством ppar-дельта-агониста
WO2012040059A2 (fr) * 2010-09-20 2012-03-29 The Regents Of The University Of California Compositions et procédés de modulation de la lipolyse adipocytaire induite par la desnutrine
EP2554182A1 (fr) * 2011-08-03 2013-02-06 Universitat Pompeu-Fabra Sestrines de mammifères pour le traitement de l'amyotrophie
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
CA2908695A1 (fr) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Antagonistes de ppar
EP3043789B1 (fr) * 2013-09-09 2020-07-08 vTv Therapeutics LLC Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire
WO2016057322A1 (fr) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Agonistes de ppar et leurs méthodes d'utilisation
WO2016057656A1 (fr) 2014-10-08 2016-04-14 Mitobridge, Inc. Agonistes ppar-delta destinés à être utilisés pour le traitement d'affections mitochondriales, vasculaires, musculaires et démyélynisantes
WO2017062468A1 (fr) 2015-10-07 2017-04-13 Mitobridge, Inc. Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
JP6925367B2 (ja) 2016-04-13 2021-08-25 ミトブリッジ,インコーポレーテッド Pparアゴニスト、化合物、医薬組成物、及びその使用方法
JP7397491B2 (ja) 2018-10-23 2023-12-13 国立研究開発法人科学技術振興機構 PPARδ活性化剤
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093874A1 (fr) * 2000-06-09 2001-12-13 Brigham Young University Procede de traitement de l'obesite et de la paralysie musculaire par des aides ergogeniques
US20050233328A1 (en) * 2001-12-03 2005-10-20 Constance Berghs Methods of identifying compounds that modulate protein activity
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
JP2007517025A (ja) * 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
AU2006269779A1 (en) * 2005-07-07 2007-01-18 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
EP2114396A4 (fr) * 2006-12-29 2010-03-10 Salk Inst For Biological Studi Procédés permettant une amélioration des performances d'exercice

Also Published As

Publication number Publication date
WO2009086526A3 (fr) 2009-09-03
AU2008345009A1 (en) 2009-07-09
EP2234622A4 (fr) 2011-03-09
WO2009086526A2 (fr) 2009-07-09
EP2234622A2 (fr) 2010-10-06
JP2011507970A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
US9192601B2 (en) Methods for enhancing muscle performance and tone
CA2710764A1 (fr) Methodes ameliorant les performances et le tonus musculaires
Terada et al. Effects of acute bouts of running and swimming exercise on PGC-1α protein expression in rat epitrochlearis and soleus muscle
Welly et al. Comparison of diet vs. exercise on metabolic function & gut microbiota in obese rats
Garcia-Roves et al. Role of calcineurin in exercise-induced mitochondrial biogenesis
Narkar et al. AMPK and PPARδ agonists are exercise mimetics
US20120134985A1 (en) Methods for modulating metabolic and circadian rhythms
Phelan et al. Carbon dioxide-dependent signal transduction in mammalian systems
Costa Júnior et al. Leucine supplementation does not affect protein turnover and impairs the beneficial effects of endurance training on glucose homeostasis in healthy mice
Reho et al. The stress of maternal separation causes misprogramming in the postnatal maturation of rat resistance arteries
US20090186949A1 (en) Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
US20120264796A1 (en) Methods for modulating circadian rhythms
US20210214329A1 (en) Novel nutrients to enhance load-induced muscle hypertrophy
Yoshino et al. Availability of saliva for the assessment of alterations in the autonomic nervous system caused by physical exercise training
Huang et al. Exercise improves high-fat diet-induced metabolic disorder by promoting HDAC5 degradation through the ubiquitin–proteasome system in skeletal muscle
CN101500610A (zh) 抗肥胖药及其利用
KR101259342B1 (ko) 비만 예방 또는 치료제의 스크리닝 방법
Li et al. Expression of the nociceptin/orphanin FQ receptor in the intestinal mucosa of IBS patients
Solomon Role of BDNF in the Ability of Exercise to Attenuate Dependence-Related Escalated Alcohol Drinking in C57BL/6J Mice
Livelo et al. Time-restricted feeding promotes skeletal muscle function in diet-and genetic-induced obesity through shared and unique pathways
Hoxha et al. Genetic variability of amino acid transporters: study of the influence on physical decline and human survival
Sampson Interrogation of Neuromedin U Receptor 2/Neuromedin U as a Novel Therapeutic Target for the Treatment of Obesity
Brandão et al. Muscle/adipose tissue crosstalk controls metabolic adaptation to exercise
CN114191433A (zh) 盐酸小檗碱在改善蛛网膜下腔出血后早期脑损伤中的应用
Reho et al. Small Vessels–Big Problems: Novel Insights into Microvascular Mechanisms of Diseases: The stress of maternal separation causes misprogramming in the postnatal maturation of rat resistance arteries

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141230